An accelerated approval process could take place. There are mechanisms within the FDA to allow for an accelerated approval process via the payment of a fee. The 6m I am assuming is the standard protocol as they would be working on 1000s of applications at one time. With the fact this was simply a resubmission of labelling and the usage process, not the drugs efficacy, an acceleration of the approval process by payment of an accelerated processing fee could in theory have this approved within the 6m period finishing mid year 2024.
Ann: Successful Completion of Human Factors Study, page-30
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $2.548M | 6.766M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 96148 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 782479 | 9 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |